Biomarker Technologies Analyzes Spatial Gene Expression Technologies for 2026

Biomarker Technologies (BMKGene) has released an analysis detailing the landscape of spatial gene expression technologies expected by 2026. The company highlights that these technologies are rapidly evolving, enabling researchers to link molecular signals directly to tissue architecture.

The analysis categorizes key approaches including sequencing-based capture, imaging-based detection, in situ hybridization, and single-cell spatial transcriptomics. These methods are designed to address diverse biological questions, offering insights at both tissue-wide and single-cell levels, or for detecting rare transcripts.

BMKGene emphasizes that the selection of an appropriate technology depends on factors such as sample type, tissue section thickness, and the specific research question. The comparison considers spatial resolution, gene coverage, compatibility with various sample types, and computational demands. The report also mentions industry players such as 10x Genomics, NanoString, Vizgen, Resolve Biosciences, and Bruker Spatial Biology.

The company stresses that no single platform is universally optimal for all experiments. Given the continuous evolution of these technologies, assessments should not be considered permanent. Making informed decisions requires practical validation, transparent reporting, and a clear alignment with the research objective. The most effective technology, according to the analysis, is the one that provides interpretable evidence from the available sample.